07.01.2019, 2803 Zeichen

Valneva: Austrian-french biotech company Valneva SE announced positive Phase 1 interim results for its Chikungunya vaccine candidate, VLA1553. The primary objective of VLA1553-101 Phase 1 study was to assess the overall safety and immunogenicity profile 28 days after a single vaccination across three dose levels. The interim results showed an excellent immunogenicity profile after a single vaccination with a 100% seroconversion rate2 achieved at Day 28 in a pooled analysis3 of all vaccinated groups. Results also showed 96.5% of subjects achieved at least a 16-fold increase in antibody titres and a high geometric mean titre, fully supporting VLA1553’s differentiated target product profile. Wolfgang Bender, Chief Medical Officer of Valneva commented, “These results mark an important milestone towards our goal of developing a single-shot vaccine against Chikungunya. We are making every commitment to advance our vaccine quickly so that we can address this serious threat to public health. Phase 1 revaccination data post month six is expected by mid-year and will be key to define development acceleration options. The recent award of FDA Fast Track designation will allow us to work closely with the FDA on this development strategy.”
Valneva: weekly performance: 6.12%

ams: ams, a leading worldwide supplier of high performance sensor solutions, and Face++, the leader in artificial intelligence software, have agreed a co-operation arrangement to accelerate OEMs’ and system integrators’ deployments of 3D optical sensing technologies such as face recognition. This partnership means that manufacturers can go to market faster with superior systems for performing functions such as face recognition, facial payments, Animoji creation and augmented/virtual reality. The 3D optical sensing solutions created by ams and Face++, which use infrared light projectors to map the surface of real-world objects such as a user’s face, are bringing about profound changes in the operation of security and authentication functions. 3D optical sensing, for instance, enables face recognition in the mobile phone, giving users an easy and secure alternative to PIN codes and fingerprint sensing for device unlocking and payment functions. "Now, by linking our 3D sensing systems with Face++ technology, we are enabling manufacturers to add these popular features to their products quickly and smoothly. Together, ams and Face++ are showing that 3D sensing solutions are ready for the mainstream now in every market sector, from consumer to automotive, medical and industrial electronics,” says Ulrich Huewels, Executive Vice-President & General Manager for Optical Sensor Solutions at ams.
AMS: weekly performance: 22.27%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (07/01/2019)

Christian Drastil: Wiener Börse Plausch

SportWoche Podcast #107: Kave Atefie, Co-Founder gesund.co.at, Maradonas Balljunge, Rocky-Box-Double, BB King Vorgruppe

Bildnachweis

Aktien auf dem Radar:Palfinger, Immofinanz, Kapsch TrafficCom, Flughafen Wien, EuroTeleSites AG, Addiko Bank, Rosgix, Telekom Austria, RBI, SBO, Uniqa, ams-Osram, Oberbank AG Stamm, Agrana, Amag, CA Immo, Erste Group, EVN, FACC, OMV, Österreichische Post, VIG, Wienerberger, Warimpex, Henkel, Apple, Amgen, Deutsche Post, Vonovia SE, Beiersdorf, Münchener Rück.

---